Bristol-Myers Squibb Co

FDA approves weekly self‑injection of Saphnelo (anifrolumab) for SLE, offering the same proven safety and efficacy of the IV drug with greater convenience for patients.

Corporate‑Market Update: Bristol‑Myers Squibb (BMY) shows steady institutional inflows, routine insider transactions, bullish call‑option volume, and solid revenue growth despite a modest EPS miss, underscoring continued confidence in BMY’s pipeline…

Volatile BMY trading, mixed analyst sentiment, and pipeline insights—discover how Bristol‑Myers Squibb balances speculation, earnings, and pharma innovation.

Explore how Bristol‑Myers Squibb’s Camzyos Phase 3 success could reshape its portfolio, opening a high‑margin pediatric cardiology niche and reducing oncology dependence.

Explore Bristol‑Myers Squibb’s 12(g) deregistration, new mental‑health partnership, and Pictet’s investment, revealing how the pharma giant is cutting compliance costs while boosting value‑based care.

Discover how Bristol‑Myers Squibb’s partnership with NCMWB could reshape schizophrenia treatment with peer‑support, predictive analytics, and new revenue streams by 2027.

Discover why Bristol‑Myers Squibb’s $0.63 dividend, Barclays praise, and steady ownership shifts signal strong investor confidence and stable stock performance.

Explore how Bristol‑Myers Squibb balances robust margins, value‑based reimbursement, and tech‑driven care to attract investors and boost patient access.

Explore Bristol‑Myers Squibb’s strong drug pipeline, solid safety record, and market resilience, and why investors view it as a stable biopharma pick.

Explore Bristol‑Myers Squibb’s latest market trends, analyst outlooks, and late‑stage oncology pipeline—discover why investors remain bullish on its future gains.